Showing 1361-1370 of 5603 results for "".
Diagnosing IBD: Is It IBD or Something Else? Can You Tell?
https://reachmd.com/programs/cme/diagnosing-ibd-is-it-ibd-or-something-else-can-you-tell/51480/Explore IBD from diagnosis to remission with practical cases, treatment strategies, and a treat-to-target approach for optimal patient outcomes.Severity Assessment: Can You Pin the Stage on the Patient?
https://reachmd.com/programs/cme/severity-assessment-can-you-pin-the-stage-on-the-patient/51481/Explore IBD from diagnosis to remission with practical cases, treatment strategies, and a treat-to-target approach for optimal patient outcomes.IBD Immunopathogenesis: Do You Know What You're Blocking?
https://reachmd.com/programs/cme/ibd-immunopathogenesis-do-you-know-what-youre-blocking/51482/Explore IBD from diagnosis to remission with practical cases, treatment strategies, and a treat-to-target approach for optimal patient outcomes.- Lighting the Way: Exploring the Potential of Photobiomodulation for Dry AMD Treatmenthttps://reachmd.com/programs/cme/Lighting-the-Way-Exploring-the-Potential-of-Photobiomodulation-for-Dry-AMD-Treatment-2512/33041/Learn about multiwavelength PBM for the treatment of dry AMD, including the MOA, administration, eff
Transformative Insights: Latest Evidence for B7-H3 ADCs From WCLC and ESMO 2025
https://reachmd.com/programs/cme/transformative-insights-latest-evidence-for-b7-h3-adcs-from-wclc-and-esmo-2025/36238/Explore recent clinical data on B7-H3 ADCs in ES-SCLC, with expert insights on biological rationale, efficacy outcomes, safety profiles, and patient selection.Pruritus In PN and AD: Challenge How You Manage Itch
https://reachmd.com/programs/cme/pruritus-in-pn-and-ad-challenge-how-you-manage-itch/36304/Use validated assessment tools to prioritize and measure itch in prurigo nodularis and atopic dermatitis in an interactive CME escape room.Translating Clinical Data Into Multidisciplinary Practice for ES-SCLC
https://reachmd.com/programs/cme/translating-clinical-data-into-multidisciplinary-practice-for-es-sclc/37878/Explore recent clinical data on B7-H3 ADCs in ES-SCLC, with expert insights on biological rationale, efficacy outcomes, safety profiles, and patient selection.GDMT Is Working Fine, Why Add More Therapies? The Clinical Rationale for Layering Therapies in Patients with HFrEF
https://reachmd.com/programs/cme/gdmt-is-working-fine-why-add-more-therapies-the-clinical-rationale-for-layering-therapies-in-patients-with-hfref/54632/Drs. Bauersachs, Butler & Lam discuss persistent residual risk in HFrEF, the use of sGC stimulators to reduce risk, and supporting evidence for this approach.Advancing Care in HNSCC: Evolving Strategies Across the Disease Continuum
https://reachmd.com/programs/cme/advancing-care-in-hnscc-evolving-strategies-across-the-disease-continuum/48999/Experts explain how emerging clinical data and novel therapeutic strategies in HNSCC can expand our treatment armamentarium and improve patient outcomes.Emerging Clinical Evidence for B7-H3–Directed ADCs in ES-SCLC From WCLC 2025
https://reachmd.com/programs/cme/emerging-clinical-evidence-for-b7-h3directed-adcs-in-es-sclc-from-wclc-2025/37877/Explore recent clinical data on B7-H3 ADCs in ES-SCLC, with expert insights on biological rationale, efficacy outcomes, safety profiles, and patient selection.